Invivyd, Inc. (IVVD) stock
IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3052% below fair value
$0.47−0.04 (-8.21%)
Close on Nov 18, 2026Market cap $138.68MP/E –Yield –
Invivyd revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Invivyd's revenue for the twelve months ending Jun 30, 2026 was $58.37M, up 26.3% year over year. For fiscal 2025 it was $53.43M, up 110.5% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.43M | +110.5% |
| FY2024 | Dec 31, 2024 | $25.38M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.29M | +21.2% |
| Q1 FY2026 | Mar 31, 2026 | $13.74M | +21.6% |
| Q4 FY2025 | Dec 31, 2025 | $17.21M | +24.5% |
| Q3 FY2025 | Sep 30, 2025 | $13.13M | +41.2% |
| Q2 FY2025 | Jun 30, 2025 | $11.79M | +420.6% |
| Q1 FY2025 | Mar 31, 2025 | $11.30M | – |
| Q4 FY2024 | Dec 31, 2024 | $13.82M | – |
| Q3 FY2024 | Sep 30, 2024 | $9.30M | – |
| Q2 FY2024 | Jun 30, 2024 | $2.26M | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?